Martin Gotthardt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martin Gotthardt has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Klaus Joseph
Department of Nuclear Medicine Philipps‐University of Marburg Baldingerstrasse 35043 Marburg Germany
6 shared publicationsHans-Walter Fritsch
Department of Nuclear Medicine, Philipps-University of Marburg, Baldingerstrasse, 35043 Marburg
3 shared publicationsThomas M. Behr
Department of Nuclear Medicine Philipps‐University of Marburg Baldingerstrasse 35043 Marburg Germany
3 shared publicationsUlrich Welcke
3 shared publicationsDésirée Brandt
2 shared publicationsHelmut Höffken
Department of Nuclear Medicine Philipps‐University of Marburg Baldingerstrasse 35043 Marburg Germany
2 shared publications
Latest Publications
- 1 September 2004
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (24) , 2951-2963
Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Peptide-based radiopharmaceuticals have been introduced into clinical work more than a decade ago. The first and most successful imaging agent to date is the somatostatin analog octreotide. It is used for somatostatin receptor scintigraphy and also receptor-mediated peptide-radiotherapy of neuroendocrine tumors. For in vivo use as radiopharmaceutical, the natural peptide is modified in order to enhance the metabolic stability and to allow stable labeling with a so-called residualizing label. This means, that a radiometal chelator complex bound to a modified peptide stable in serum is internalized into the target cells via a specific receptor. The peptide then undergoes lysosomal degradation leaving the radiometal-chelator complex trapped inside the cell, leading to a high target to background ratio. The successful development of new radiopeptides is thus dependent on modifications of a given natural peptide while preserving the binding affinity for the target receptor(s) at the same time. Other peptides than somatostatin are under development for use as radiopeptides such as Minigastrin, GLP-1, VIP, Substance P, or Neurotensin. Some show very favorable results in clinical trials, like Minigastrin for example. Furthermore, there is increasing interest in peptidebinding sites other than the “classical” receptors for regulatory peptides specifically over-expressed by (neuroendocrine) tumors. In this paper, we provide an overview of the biochemical and radiochemical aspects of radiopeptide development, the current state of clinical use of radiopeptides for diagnosis and therapy of tumors, the current state of development of new compounds, and future developments.
- 1 September 2004
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (24) , 2951-2963
Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Peptide-based radiopharmaceuticals have been introduced into clinical work more than a decade ago. The first and most successful imaging agent to date is the somatostatin analog octreotide. It is used for somatostatin receptor scintigraphy and also receptor-mediated peptide-radiotherapy of neuroendocrine tumors. For in vivo use as radiopharmaceutical, the natural peptide is modified in order to enhance the metabolic stability and to allow stable labeling with a so-called residualizing label. This means, that a radiometal chelator complex bound to a modified peptide stable in serum is internalized into the target cells via a specific receptor. The peptide then undergoes lysosomal degradation leaving the radiometal-chelator complex trapped inside the cell, leading to a high target to background ratio. The successful development of new radiopeptides is thus dependent on modifications of a given natural peptide while preserving the binding affinity for the target receptor(s) at the same time. Other peptides than somatostatin are under development for use as radiopeptides such as Minigastrin, GLP-1, VIP, Substance P, or Neurotensin. Some show very favorable results in clinical trials, like Minigastrin for example. Furthermore, there is increasing interest in peptidebinding sites other than the “classical” receptors for regulatory peptides specifically over-expressed by (neuroendocrine) tumors. In this paper, we provide an overview of the biochemical and radiochemical aspects of radiopeptide development, the current state of clinical use of radiopeptides for diagnosis and therapy of tumors, the current state of development of new compounds, and future developments.
- 26 November 2003
- Published by Wiley in World Journal of Surgery
- Vol. 28 (1) , 100-107
Clinical Value of Parathyroid Scintigraphy with Technetium‐99m Methoxyisobutylisonitrile: Discrepancies in Clinical Data and a Systematic Metaanalysis of the Literature
There is a considerable discrepancy in the literature concerning the sensitivity of parathyroid scintigraphy (PS) with 99mTc‐MIBI. We therefore analyzed our own data and compared them to the literature in a metaanalysis. All patients who received 99mTc ‐MIBI scintigraphy and subsequent surgery in our department for the detection of enlarged parathyroid glands in primary (pHPT) or secondary (sHPT) hyperparathyroidism between 1991 and 1999 were included in our retrospective analysis. The results of surgery served as the gold standard. For a true positive result, the scintigraphy had to predict the exact location of parathyroid adenoma (PA) or parathyroid hyperplasia (PH). We then compared these data to the results of a nonstatistical systematic metaanalysis of the literature. Patients (178) underwent PS between 1991 and 1999; 139 were operated on and included in this study. Of these, 109 had pHPT and 30 had sHPT. The sensitivity and specificity of the PS were found to be 45% / 94% for pHPT and 39% / 40% for sHPT. Fifty‐two studies concerning PS were included in the metaanalysis. Sensitivities reported varied from 39% to > 90%. Consideration of the different possible techniques used for PS could not explain these discrepancies. Our data show that the sensitivity of PS in clinical routine may be lower than expected from the literature. Our data are consistent with other studies and with partially unpublished clinical observations from other university hospitals. We believe that a well‐designed and properly conducted prospective study is necessary to evaluate the reasons for the differences observed.
- 26 November 2003
- Published by Wiley in World Journal of Surgery
- Vol. 28 (1) , 100-107
Clinical Value of Parathyroid Scintigraphy with Technetium‐99m Methoxyisobutylisonitrile: Discrepancies in Clinical Data and a Systematic Metaanalysis of the Literature
There is a considerable discrepancy in the literature concerning the sensitivity of parathyroid scintigraphy (PS) with 99mTc‐MIBI. We therefore analyzed our own data and compared them to the literature in a metaanalysis. All patients who received 99mTc ‐MIBI scintigraphy and subsequent surgery in our department for the detection of enlarged parathyroid glands in primary (pHPT) or secondary (sHPT) hyperparathyroidism between 1991 and 1999 were included in our retrospective analysis. The results of surgery served as the gold standard. For a true positive result, the scintigraphy had to predict the exact location of parathyroid adenoma (PA) or parathyroid hyperplasia (PH). We then compared these data to the results of a nonstatistical systematic metaanalysis of the literature. Patients (178) underwent PS between 1991 and 1999; 139 were operated on and included in this study. Of these, 109 had pHPT and 30 had sHPT. The sensitivity and specificity of the PS were found to be 45% / 94% for pHPT and 39% / 40% for sHPT. Fifty‐two studies concerning PS were included in the metaanalysis. Sensitivities reported varied from 39% to > 90%. Consideration of the different possible techniques used for PS could not explain these discrepancies. Our data show that the sensitivity of PS in clinical routine may be lower than expected from the literature. Our data are consistent with other studies and with partially unpublished clinical observations from other university hospitals. We believe that a well‐designed and properly conducted prospective study is necessary to evaluate the reasons for the differences observed.
- 1 September 2003
- Published by Elsevier in Clinical Lung Cancer
- Vol. 5 (2) , 119-124
Imaging Lung Tumors with Peptide-Based Radioligands
- 1 September 2003
- Published by Elsevier in Clinical Lung Cancer
- Vol. 5 (2) , 119-124
Imaging Lung Tumors with Peptide-Based Radioligands
- 1 May 2002
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 23 (5) , 447-452
Follow-up of perfusion defects in pulmonary perfusion scanning after pulmonary embolism: are we too careless?
Persisting perfusion defects may still be found in pulmonary perfusion scintigraphy months or years after pulmonary embolism. The aim of this study was to investigate the rate of persisting perfusion defects and the pattern of scintigraphic follow-up of patients after pulmonary embolism. Only those patients were included into our study who received pulmonary perfusion scintigraphy between 1991 and 1999, and who had perfusion defects including at least one whole segment. These perfusion defects were considered as persisting perfusion defects if unchanged over at least 1 year. From 3640 patients examined, 451 (12.4%) had perfusion defects meeting the criteria of this study. Of those, 129 (28.6%) received a scintigraphic follow-up. In 62 patients (48.1%), a reperfusion of the defects was found. In 38 patients (29.5%), the defects persisted within a follow-up period of up to 12 weeks. However, no pulmonary perfusion scintigraphy was performed thereafter. Out of the 129 patients receiving a scintigraphic follow-up, only 29 (22.5%) had a follow-up over more than 1 year, 19 of those had persisting perfusion defects. It is concluded that our data show an inadequate scintigraphic follow-up of patients with pulmonary embolism which may lead to unnecessary anticoagulant treatment if persisting perfusion defects are misinterpreted as fresh pulomary embolism. In many cases, there was no further follow-up even if reperfusion of the defects was lacking in early follow-up.
- 1 May 2002
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 23 (5) , 447-452
Follow-up of perfusion defects in pulmonary perfusion scanning after pulmonary embolism: are we too careless?
Persisting perfusion defects may still be found in pulmonary perfusion scintigraphy months or years after pulmonary embolism. The aim of this study was to investigate the rate of persisting perfusion defects and the pattern of scintigraphic follow-up of patients after pulmonary embolism. Only those patients were included into our study who received pulmonary perfusion scintigraphy between 1991 and 1999, and who had perfusion defects including at least one whole segment. These perfusion defects were considered as persisting perfusion defects if unchanged over at least 1 year. From 3640 patients examined, 451 (12.4%) had perfusion defects meeting the criteria of this study. Of those, 129 (28.6%) received a scintigraphic follow-up. In 62 patients (48.1%), a reperfusion of the defects was found. In 38 patients (29.5%), the defects persisted within a follow-up period of up to 12 weeks. However, no pulmonary perfusion scintigraphy was performed thereafter. Out of the 129 patients receiving a scintigraphic follow-up, only 29 (22.5%) had a follow-up over more than 1 year, 19 of those had persisting perfusion defects. It is concluded that our data show an inadequate scintigraphic follow-up of patients with pulmonary embolism which may lead to unnecessary anticoagulant treatment if persisting perfusion defects are misinterpreted as fresh pulomary embolism. In many cases, there was no further follow-up even if reperfusion of the defects was lacking in early follow-up.
- 6 March 2002
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 29 (5) , 597-606
Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results
The non-invasive detection of insulinomas remains a diagnostic problem that is not solved by means of somatostatin receptor scintigraphy. We investigated the biokinetics and specificity of uptake and degradation of the incretin hormone glucagon-like peptide-1 (GLP-1) in a rat insulinoma cell line (RINm5F) in order to ascertain whether radiolabelled GLP-1 may be suitable for specific visualisation of insulinomas in vivo. GLP-1 (7–36)amide was radioiodinated according to the iodogen method. The specificity of the uptake of [125I]GLP-1(7–36)amide by RINm5F cells was investigated. Degradation products of GLP-1 (7–36)amide in the cell medium were purified by HPLC. Their masses and amino acid sequences were determined by 252Cf-plasma desorption mass spectrometry. Lysosomal degradation was inhibited and after differential centrifugation the amount of radiotracer incorporated into lysosomes was determined. Biodistribution studies were performed in a rat insulinoma model (NEDH rats and RINm5F cells) with [123I]GLP-1(7–36)amide and its more stable agonist [123I]exendin 3. The uptake of radiotracer into insulinoma cells reached a maximum within 5 min. It was inhibited by an excess of unlabelled peptide. [125I]GLP-1(7–36)amide accumulated in the cells if lysosomal degradation was inhibited. Degradation products of the peptide were found in the cell medium. We determined their mass and derived their amino acid sequence. Radiolabelling of exendin 3 was more difficult than that of GLP-1 because of the lack of tyrosine in its primary structure. Biodistribution studies showed rapid blood clearance and uptake of the radiotracer into the tumour and the pancreas. It was also possible to detect insulinomas in an animal model by external scintigraphy using radioiodinated GLP-1 (7–36)amide and exendin 3. GLP-1 (7–36)amide is specifically internalised into insulinoma cells by a receptor-mediated mechanism. Our results demonstrate that GLP-1 receptor-directed scintigraphy may be a new method for the detection of insulinomas in vivo. Due to the short half-life of GLP-1, its more stable analogue exendin 3 may better suit this purpose in vivo.
- 6 March 2002
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 29 (5) , 597-606
Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results
The non-invasive detection of insulinomas remains a diagnostic problem that is not solved by means of somatostatin receptor scintigraphy. We investigated the biokinetics and specificity of uptake and degradation of the incretin hormone glucagon-like peptide-1 (GLP-1) in a rat insulinoma cell line (RINm5F) in order to ascertain whether radiolabelled GLP-1 may be suitable for specific visualisation of insulinomas in vivo. GLP-1 (7–36)amide was radioiodinated according to the iodogen method. The specificity of the uptake of [125I]GLP-1(7–36)amide by RINm5F cells was investigated. Degradation products of GLP-1 (7–36)amide in the cell medium were purified by HPLC. Their masses and amino acid sequences were determined by 252Cf-plasma desorption mass spectrometry. Lysosomal degradation was inhibited and after differential centrifugation the amount of radiotracer incorporated into lysosomes was determined. Biodistribution studies were performed in a rat insulinoma model (NEDH rats and RINm5F cells) with [123I]GLP-1(7–36)amide and its more stable agonist [123I]exendin 3. The uptake of radiotracer into insulinoma cells reached a maximum within 5 min. It was inhibited by an excess of unlabelled peptide. [125I]GLP-1(7–36)amide accumulated in the cells if lysosomal degradation was inhibited. Degradation products of the peptide were found in the cell medium. We determined their mass and derived their amino acid sequence. Radiolabelling of exendin 3 was more difficult than that of GLP-1 because of the lack of tyrosine in its primary structure. Biodistribution studies showed rapid blood clearance and uptake of the radiotracer into the tumour and the pancreas. It was also possible to detect insulinomas in an animal model by external scintigraphy using radioiodinated GLP-1 (7–36)amide and exendin 3. GLP-1 (7–36)amide is specifically internalised into insulinoma cells by a receptor-mediated mechanism. Our results demonstrate that GLP-1 receptor-directed scintigraphy may be a new method for the detection of insulinomas in vivo. Due to the short half-life of GLP-1, its more stable analogue exendin 3 may better suit this purpose in vivo.
- 1 June 2000
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 25 (6) , 414-420
The Role of Bone Scintigraphy in Patients With Erdheim–Chester Disease
Erdheim–Chester disease (ECD) is a rare disorder that has been reported fewer than 60 times in the literature. Although clinical findings seem to be specific at first sight, histologic classification remains unclear. It has not been decided whether ECD is part of the spectrum of histiocytoses or whether it may be a lipid storage disorder or even a primary macrophage cell disorder, although it does show a distinct histologic pattern. However, the clinical appearance alone shows several typical features, rendering the diagnosis very probable if present. This article illustrates the importance of bone scanning in ECD, because the scintigraphic pattern of involved skeletal sites may in themselves lead to the diagnosis. Several differential diagnoses are considered. The importance of bone scintigraphy as an imaging method in patients with an unclear diagnosis is discussed, as exemplary in ECD, as is its role for the detection of sites of skeletal involvement in other diseases.
- 1 June 2000
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 25 (6) , 414-420
The Role of Bone Scintigraphy in Patients With Erdheim–Chester Disease
Erdheim–Chester disease (ECD) is a rare disorder that has been reported fewer than 60 times in the literature. Although clinical findings seem to be specific at first sight, histologic classification remains unclear. It has not been decided whether ECD is part of the spectrum of histiocytoses or whether it may be a lipid storage disorder or even a primary macrophage cell disorder, although it does show a distinct histologic pattern. However, the clinical appearance alone shows several typical features, rendering the diagnosis very probable if present. This article illustrates the importance of bone scanning in ECD, because the scintigraphic pattern of involved skeletal sites may in themselves lead to the diagnosis. Several differential diagnoses are considered. The importance of bone scintigraphy as an imaging method in patients with an unclear diagnosis is discussed, as exemplary in ECD, as is its role for the detection of sites of skeletal involvement in other diseases.
- 1 April 2000
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 25 (4) , 291-292
Venous Bypass After Deep Venous Thrombosis Visible on an Early-Phase Bone Scan
Bone scintigraphy was performed on a 66-year-old woman because of pain in the left hip 5 years after prosthetic replacement of the joint. Loosening of the prosthesis was suspected. Changes secondary to a prior deep vein thrombosis and superficial vein prominence were seen.
- 1 April 2000
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 25 (4) , 291-292
Venous Bypass After Deep Venous Thrombosis Visible on an Early-Phase Bone Scan
Bone scintigraphy was performed on a 66-year-old woman because of pain in the left hip 5 years after prosthetic replacement of the joint. Loosening of the prosthesis was suspected. Changes secondary to a prior deep vein thrombosis and superficial vein prominence were seen.
- 1 March 2000
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 25 (3) , 210-212
Huge Necrotic Liver Metastases in Advanced Pancreatic Carcinoma Visualized on Bone Scans
A 49-year-old man had a histologically confirmed pancreatic carcinoma with several huge necrotic metastases in the liver. Many cases of increased radionuclide uptake in liver metastases have been reported, but in this case the radionuclide uptake was missing.
- 1 March 2000
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 25 (3) , 210-212
Huge Necrotic Liver Metastases in Advanced Pancreatic Carcinoma Visualized on Bone Scans
A 49-year-old man had a histologically confirmed pancreatic carcinoma with several huge necrotic metastases in the liver. Many cases of increased radionuclide uptake in liver metastases have been reported, but in this case the radionuclide uptake was missing.
- 1 August 1999
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 24 (8) , 603-604
Persistent Segmental Perfusion Defect in an Intermediate-Probability Lung Scan
A perfusion defect persisting for 11 years in a 37-year-old woman is described. This area demonstrated a V/Q mismatch but was not caused by pulmonary embolism.
- 1 August 1999
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 24 (8) , 603-604
Persistent Segmental Perfusion Defect in an Intermediate-Probability Lung Scan
A perfusion defect persisting for 11 years in a 37-year-old woman is described. This area demonstrated a V/Q mismatch but was not caused by pulmonary embolism.